SOPHIA GENETICS SA (SOPH) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SOPH • CH1125843347

4.78 USD
0 (0%)
Last: Feb 11, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall SOPH gets a fundamental rating of 2 out of 10. We evaluated SOPH against 35 industry peers in the Health Care Technology industry. Both the profitability and financial health of SOPH have multiple concerns. SOPH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year SOPH has reported negative net income.
  • SOPH had a negative operating cash flow in the past year.
  • In the past 5 years SOPH always reported negative net income.
  • In the past 5 years SOPH always reported negative operating cash flow.
SOPH Yearly Net Income VS EBIT VS OCF VS FCFSOPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • The Return On Assets of SOPH (-51.10%) is worse than 74.29% of its industry peers.
  • SOPH's Return On Equity of -87.58% is on the low side compared to the rest of the industry. SOPH is outperformed by 74.29% of its industry peers.
Industry RankSector Rank
ROA -51.1%
ROE -87.58%
ROIC N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
SOPH Yearly ROA, ROE, ROICSOPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • SOPH has a Gross Margin of 67.52%. This is in the better half of the industry: SOPH outperforms 62.86% of its industry peers.
  • SOPH's Gross Margin has been stable in the last couple of years.
  • SOPH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
SOPH Yearly Profit, Operating, Gross MarginsSOPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • SOPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • SOPH has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SOPH has been increased compared to 5 years ago.
  • The debt/assets ratio for SOPH is higher compared to a year ago.
SOPH Yearly Shares OutstandingSOPH Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
SOPH Yearly Total Debt VS Total AssetsSOPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • SOPH has an Altman-Z score of -1.09. This is a bad value and indicates that SOPH is not financially healthy and even has some risk of bankruptcy.
  • SOPH has a worse Altman-Z score (-1.09) than 65.71% of its industry peers.
  • A Debt/Equity ratio of 0.33 indicates that SOPH is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.33, SOPH is not doing good in the industry: 65.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -1.09
ROIC/WACCN/A
WACC5.01%
SOPH Yearly LT Debt VS Equity VS FCFSOPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • SOPH has a Current Ratio of 3.11. This indicates that SOPH is financially healthy and has no problem in meeting its short term obligations.
  • SOPH has a Current ratio of 3.11. This is in the better half of the industry: SOPH outperforms 65.71% of its industry peers.
  • SOPH has a Quick Ratio of 2.94. This indicates that SOPH is financially healthy and has no problem in meeting its short term obligations.
  • SOPH has a Quick ratio (2.94) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.11
Quick Ratio 2.94
SOPH Yearly Current Assets VS Current LiabilitesSOPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • SOPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.92%.
  • Looking at the last year, SOPH shows a quite strong growth in Revenue. The Revenue has grown by 13.66% in the last year.
  • SOPH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.78% yearly.
EPS 1Y (TTM)-0.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)13.66%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%22.77%

3.2 Future

  • SOPH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.43% yearly.
  • The Revenue is expected to grow by 21.47% on average over the next years. This is a very strong growth
EPS Next Y-19.98%
EPS Next 2Y1.8%
EPS Next 3Y6.43%
EPS Next 5YN/A
Revenue Next Year16.18%
Revenue Next 2Y16%
Revenue Next 3Y16.52%
Revenue Next 5Y21.47%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
SOPH Yearly Revenue VS EstimatesSOPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M
SOPH Yearly EPS VS EstimatesSOPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • SOPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SOPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SOPH Price Earnings VS Forward Price EarningsSOPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SOPH Per share dataSOPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.8%
EPS Next 3Y6.43%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SOPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SOPHIA GENETICS SA

NASDAQ:SOPH (2/11/2026, 8:00:02 PM)

4.78

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-04
Earnings (Next)03-03
Inst Owners39.28%
Inst Owner Change0.23%
Ins Owners6.43%
Ins Owner ChangeN/A
Market Cap324.32M
Revenue(TTM)73.30M
Net Income(TTM)-74.98M
Analysts86
Price Target7.48 (56.49%)
Short Float %0.08%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.93%
Min EPS beat(2)-40.66%
Max EPS beat(2)-13.2%
EPS beat(4)0
Avg EPS beat(4)-14.38%
Min EPS beat(4)-40.66%
Max EPS beat(4)-0.67%
EPS beat(8)2
Avg EPS beat(8)-8.3%
EPS beat(12)5
Avg EPS beat(12)0.72%
EPS beat(16)8
Avg EPS beat(16)4.71%
Revenue beat(2)2
Avg Revenue beat(2)4.02%
Min Revenue beat(2)2.77%
Max Revenue beat(2)5.27%
Revenue beat(4)3
Avg Revenue beat(4)2.28%
Min Revenue beat(4)-1.89%
Max Revenue beat(4)5.27%
Revenue beat(8)3
Avg Revenue beat(8)-1.67%
Revenue beat(12)5
Avg Revenue beat(12)-1.07%
Revenue beat(16)5
Avg Revenue beat(16)-1.47%
PT rev (1m)0%
PT rev (3m)4.76%
EPS NQ rev (1m)-3.26%
EPS NQ rev (3m)-1.06%
EPS NY rev (1m)-0.98%
EPS NY rev (3m)-3.71%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)0.12%
Revenue NY rev (1m)0.13%
Revenue NY rev (3m)1.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.42
P/FCF N/A
P/OCF N/A
P/B 3.79
P/tB 5.83
EV/EBITDA N/A
EPS(TTM)-1.1
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS1.08
BVpS1.26
TBVpS0.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.1%
ROE -87.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.52%
FCFM N/A
ROA(3y)-38.14%
ROA(5y)-33.44%
ROE(3y)-53.54%
ROE(5y)-45.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.64%
GM growth 5Y-0.84%
F-Score2
Asset Turnover0.5
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.33%
Cap/Sales 11.05%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.11
Quick Ratio 2.94
Altman-Z -1.09
F-Score2
WACC5.01%
ROIC/WACCN/A
Cap/Depr(3y)130.72%
Cap/Depr(5y)142.16%
Cap/Sales(3y)16.39%
Cap/Sales(5y)15.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-19.98%
EPS Next 2Y1.8%
EPS Next 3Y6.43%
EPS Next 5YN/A
Revenue 1Y (TTM)13.66%
Revenue growth 3Y17.23%
Revenue growth 5Y20.78%
Sales Q2Q%22.77%
Revenue Next Year16.18%
Revenue Next 2Y16%
Revenue Next 3Y16.52%
Revenue Next 5Y21.47%
EBIT growth 1Y-1.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year36.52%
EBIT Next 3Y16.72%
EBIT Next 5Y18.33%
FCF growth 1Y19.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.44%
OCF growth 3YN/A
OCF growth 5YN/A

SOPHIA GENETICS SA / SOPH FAQ

What is the fundamental rating for SOPH stock?

ChartMill assigns a fundamental rating of 2 / 10 to SOPH.


Can you provide the valuation status for SOPHIA GENETICS SA?

ChartMill assigns a valuation rating of 0 / 10 to SOPHIA GENETICS SA (SOPH). This can be considered as Overvalued.


How profitable is SOPHIA GENETICS SA (SOPH) stock?

SOPHIA GENETICS SA (SOPH) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for SOPH stock?

The Earnings per Share (EPS) of SOPHIA GENETICS SA (SOPH) is expected to decline by -19.98% in the next year.